High dose chemotherapy (HDT) with autologous hematopoietic stem cell transplantation (PBSCT) significantly improves survival in multiple (MM) patients. However, in a subgroup of patients early relapses occur. In order to investigate whether the amount of residual tumor cells in the bone marrow (BM) after transplantation can predict the timing of relapse, a quantitative PCR assay was used to measure tumor load in BM at 3 and 6 months posttransplant in 68 patients with MM. In 45 patients, HDT comprised a single cycle of 140 mg/m2 and total body irradiation of 12 Gy (EBMT phase III trial on CD34-selection), in 22 patients two sequential cycles of melphalan 200 mg/m2 were administered (GMMG-1998 trial) , and one patient received a single cycle of melphalan 200 mg. All patients received PBSCT, either CD34+-selected or unselected. In 61 patients, the BM tumor load at 3 months was analyzed and in 29 of these the 6 months value was also determined. In 7 patients, the tumor load was investigated at 6 months only. The myeloma Ig heavy chain variable sequence was used as a tumor specific target, and quantitation was performed by limiting dilution. The median level of tumor cells in the BM was 380 per 10E6 total mononucleated cells (MNC) at 3 months post-PBSCT (range, 1 to 25,900; n=61) , and 279 at 6 months (range, 2 to 70,000; n=36). Previous analysis of a smaller group of patients had suggested that a threshold value of 200 tumor cells per 10E6 MNC (0.02%) at 3 or 6 months posttransplant might predict outcome. Therefore, we determined whether this threshold value of (0.02%) tumor cells could again place patients into a good or bad prognostic group. For patients with a lower tumor burden (n=23), the progression-free survival (PFS) was 70% at 2 years vs. 50% for patients with more than 200 tumor cells per 10E6 MNC at either time point (n=45). This difference was statistically significant (p=0.007). The kinetics of MRD between 3 to 6 months after PBSCT were evaluable in 29 patients. PFS at 2 years was 56% in those patients with no increase in tumor burden (n=14) vs. 34% in those who showed a rise in tumor burden (p=ns). In conclusion: quantitative molecular monitoring may help t o discriminate between low and high risk groups of patients 3 to 6 months after transplantation, and thus to identify those patients who are in need of further treatment after PBSCT. Ovarian cancer is one of the leading cancer death in women. Despite the high response rate, patients (pts) with advanced ovarian cancer have a poor long term survival with a very high percentage of relapse and only 25-30 % remain alive at 5 yrs. HDC has a potential benefit in pts in remission and randomized trials are ongoing. We performed a retrospective analysis on 77 pts with ovarian carcinoma in 1st CR treated with high dose chemotherapy (HDC) and hemopoietic support from 20 centres of EBMT group. Median age was 48 years (range 15-64), median PS 0 (0-2), median number of conventional chemotherapy courses before HDC was 6 (range 2-9). After surgery, 14 pts had no residual disease (RD), 24 pts <2 cm, 19 pts >2 cm. After induction chemotherapy 14 pts (18%) were in pCR, 8 pts (10%) had microscopic RD, and 40 pts (52%) were in cCR. Interval debulking surgery was performed on 24 pts. Fifty-one pts received a single course of HDC; 26 pts received multiple cycles of HDC (from 2 to 5). Hemopoietic stem cell support was bone marrow in the 21 % and peripheral blood in 79 % of the pts. With a median follow up of 4 years (range 0.5-11), median (95% CI) time to progression (TTP) and overall survival (OS) of all patients were 19.4 mos (10-29) and 46.5 mos (37-55.7) respectively. According to RD after surgery, median (95% CI) TTP and OS for pts with no RD have not yet been reached: at 8 years, PFS and OS are 52% and 73% respectively. Median TTP (95 % CI) for pts with RD <2 cm and >2 cm were 13,5 mos (7, (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 4) . Tumor grade, source of stem cells and type of cytokine (G-CSF vs. GM-CSF) had no impact on TTP and/or OS. In conclusion these data show interesting long-term progression-free and overall survival rates after high-dose consolidation therapy in advanced ovarian cancer in complete response (clinical or pathological) after induction chemotherapy. Due to the limited number of pts no prognostic factor has shown a significant impact on survival.
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Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells G.U. Grigoleit, S. Riegler, H. Hebart, K. Laib, G. Jahn, P. Brossart, C. Sinzger, H. Einsele (Tuebingen, D) Antigen-presenting cells (APCs) are targets of human cytomegalovirus (HCMV) infection. Infection of these cells might either result in presentation of viral antigens to immune effector cells or in virus-induced inhibition of antigen presentation. But, HCMV infection is known to induce a state of immunodeficiency. We tested the hypothesis that productive HCMV infection of monocyte-derived immature dendritic cells (DCs) is associated with decreased immunostimulatory capacity. DCs generated from PBMNCs of healthy HCMV-seronegative donors were infected with 60 -80 % efficiency by the endothelotropic HCMV strain TB40/E. Infected versus uninfected cells were analyzed by FACS and by immunocytochemistry for surface expression of the immediate early antigen (IEA), MHC and costimulatory molecules (CD80, CD86 and CD40) as well as cytokine secretion (IL-1, IL-6, IL-10, IL-15, IL-8 and TNF-alpha) during 3 days after infection. The immunostimulatory capacity of these cells was measured by mixed leukocyte reaction. In spite of the fact that HCMV infection of DCs induced an increased release of TNF-alpha and a decreased IL-10 production, expression of MHC class I and II, as well as CD40 and CD80 molecules were downregulated on infected DCs. The mixed leukocyte reaction showed significantly reduced immunostimulatory capacity of infected DC cultures. In contrast, expression of CD1a and CD83 was not significantly different between non-infected and infected DCs. Simultaneous detection of MHC antigens and virus antigens by double immunofluorescence revealed, that downregulation occurred only
